Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00445653 · ClinicalTrials.gov registry record
Risk Factors for Barrett's Esophagus in Patients With BE, Gastroesophageal Reflux, or Gastrointestinal Bleeding
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 170
- Enrollment target
NCT00445653: Completed study, sponsored by Massachusetts General Hospital.
NCT00445653 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 170 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00445653 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 170 participants
- Enrollment target
Study Summary
RATIONALE: A study that evaluates DNA changes and other disease-related health information in patients with Barrett's esophagus, gastroesophageal reflux, or gastrointestinal bleeding may help doctors learn more about the risk factors for Barrett's esophagus. PURPOSE: This clinical trial is looking at DNA changes and other disease-related health information as risk factors for Barrett's esophagus in patients with Barrett's esophagus, gastroesophageal reflux, or gastrointestinal bleeding.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2005-08 |
| Est. Completion | 2013-03 |
What the finished NCT00445653 record still lists
NCT00445653 is an observational study that tracks outcomes without assigning an intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00445653 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00445653 about?
NCT00445653 is a clinical study titled "Risk Factors for Barrett's Esophagus in Patients With BE, Gastroesophageal Reflux, or Gastrointestinal Bleeding". RATIONALE: A study that evaluates DNA changes and other disease-related health information in patients with Barrett's esophagus, gastroesophageal reflux, or gastrointestinal bleeding may help doctors learn more about the risk factors for Barrett's esophagus. PURPOSE: This clinical trial is looking ...
What is the current status of trial NCT00445653?
This trial is currently completed. The enrollment target is 170 participants. The study started on 2005-08. Estimated completion is 2013-03.
Who is sponsoring clinical trial NCT00445653?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia